NorthWest Biotherapeutics Inc (NWBO)

[sentiment_stocks]

It's not about the dilution (companies need to raise funds), it's about silence.

I get your frustration, I really do. And I would like answers as well. I can hardly wait for some answers! But let's take note of their recent disclosures which - while it may not be the information you want to hear right now - cannot be described as them being "silent." They are giving considerable information with these following seven disclosures over the past three and a half months.

December 1, 2107
NWBO enters into material agreement for $12million for preferred shares and warrants - none of which can be sold for up to 6 months
https://www.sec.gov/Archives/edgar/data/1072379/000114420417062799/tv480895_8k.htm

November 20, 2017
10Q filed - learn brief information about Cognate debt for share swap at average .24¢ including both shares and warrants
https://www.sec.gov/Archives/edgar/data/1072379/000114420417060217/tv479903_10q.htm

November 20, 2017
NW Bio Issues Notice Of Proposed Agreement To Settle Shareholder Derivative Lawsuit
https://www.nwbio.com/nw-bio-issues-notice-proposed-agreement-settle-shareholder-derivative-lawsuit/

October 25, 2017
NW Bio Reports Favorable Results and Progress In Resolving Lawsuits

https://www.nwbio.com/nw-bio-reports-favorable-results-progress-resolving-lawsuits/

October 17, 2017
NW Bio Leases Out Warehouse On UK Property to Major Commodities Distribution Firm

September 21, 2107
"anticipating the disclosure of interim blinded data from the Company's Phase 3 trial of DCVax-L"
https://www.sec.gov/Archives/edgar/data/1072379/000114420417049289/v475690_8k.htm

August 31, 2017
Dr. Bosch gives what updates he can at presentation
https://www.nwbio.com/Boston-slides-31Aug2017-v0.5.pdf


Out of these seven communications, two have given very limited information concerning the trial. But to advocate that the company is being silent is not really entirely accurate. I'll admit, however, that they are definitely still being close-lipped about some very important subjects such the status of the trial, OS, PFS, endpoints being reached, and the investigation.

I would suggest, however, that it's highly unlikely that they are going to issue an 8-K or a Press Release stating that they aren't going to tell us what they aren't going to tell us. I'm doubting any would find it very satisfying for them to state that they are still eagerly anticipating the disclosure of interim blinded data, as that would likely be the extent of what they would say.

They've been accused in the past of issuing pumping PRs and I think it's fairly obvious they are not going to do anything that could be interpreted as that any more.